secwatch.observer — SEC 8-K summary
======================================

Issuer:     Artiva Biotherapeutics, Inc. (ARTV)
CIK:        0001817241
Form:       8-K
Filed at:   2024-08-29T23:59:59+00:00
Accession:  0001193125-24-209920
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Artiva reports Q2 net loss $17.8M; IPO raises $179M extending cash runway through 2026
--------------------------------------------------------------------------------

- IPO in July 2024 raised $179M gross; cash $46.6M pre-IPO, runway now through 2026.
- Net loss Q2 2024: $17.8M vs $11.3M YoY; R&D expense $12.3M (up 9%).
- Collaboration revenue $0 vs $3.5M in Q2 2023 after Merck deal termination.
- First patient dosed in autoimmune basket trial (AlloNK + rituximab); first LN patient in Phase 1/1b.
- Expect initial AlloNK autoimmune data in H1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817241/000119312524209920/0001193125-24-209920-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817241/000119312524209920/d890088d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-209920

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer